{"disease":{"id":"diabetic-macular-edema-dme","name":"diabetic macular edema dme"},"drugs":{"marketed":[{"drug_id":"ranibizumab-eqrn","indication_name":"Diabetic Macular Edema (DME)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07308639","title":"DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06929143","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06957080","title":"A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1054,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT04543331","title":"Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema","phase":"","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07515079","title":"Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":406,"lead_sponsor_name":"Bio-Thera Solutions","has_results":false},{"nct_id":"NCT07514559","title":"Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":393,"lead_sponsor_name":"Hospital Hietzing","has_results":false},{"nct_id":"NCT04739306","title":"Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":348,"lead_sponsor_name":"Celltrion","has_results":true},{"nct_id":"NCT07301775","title":"Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":166,"lead_sponsor_name":"Ahmad Zeeshan Jamil","has_results":false},{"nct_id":"NCT07484074","title":"A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Ollin Biosciences, Inc.","has_results":false},{"nct_id":"NCT07459829","title":"Study of CU06-1004 in Patients With Daibetic Macular Edema","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":156,"lead_sponsor_name":"Curacle Co., Ltd.","has_results":false},{"nct_id":"NCT02424019","title":"Phase 4 IOP Signals Associated With ILUVIEN®","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Alimera Sciences","has_results":false},{"nct_id":"NCT03866005","title":"Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"ZeaVision, LLC","has_results":false},{"nct_id":"NCT06116916","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT06914778","title":"Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Hywel Dda Health Board","has_results":false},{"nct_id":"NCT07338097","title":"Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":116,"lead_sponsor_name":"CMH Multan Institute of Medical Sciences","has_results":false},{"nct_id":"NCT07438119","title":"Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":114,"lead_sponsor_name":"Kun Liu","has_results":false},{"nct_id":"NCT07520045","title":"Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Osijek University Hospital","has_results":false},{"nct_id":"NCT03635814","title":"The Study to YD312 Tablet in Patients With Diabetic Macular Edema","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"YD Global Life Science Co., Ltd.","has_results":false},{"nct_id":"NCT02585401","title":"Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada","phase":"","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06882551","title":"Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"Khyber Teaching Hospital","has_results":false},{"nct_id":"NCT06846073","title":"Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07457632","title":"Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional Chinese Medicine.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":69,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT04857996","title":"Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Unity Biotechnology, Inc.","has_results":true},{"nct_id":"NCT06879301","title":"Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT06929507","title":"Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University Hospital, Alexandroupolis","has_results":false},{"nct_id":"NCT02633852","title":"Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Hadassah Medical Organization","has_results":false},{"nct_id":"NCT06664502","title":"A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT05989126","title":"Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05919693","title":"A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT03859245","title":"Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Bristlecone Health, Inc.","has_results":false},{"nct_id":"NCT06662994","title":"High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Retina Consultants of Orange County","has_results":false},{"nct_id":"NCT04697758","title":"Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"AsclepiX Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06398080","title":"An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":33},"guidelines":[],"source":"Drug Landscape verified database"}